Letrozole and ribociclib and Rifadin IV Intravenous
Determining the interaction of Letrozole and ribociclib and Rifadin IV Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using ribociclib together with rifAMPin is not recommended. Combining these medications may significantly reduce the blood levels of ribociclib, which may make the medication less effective in treating your cancer. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with potent CYP450 3A4 inducers may significantly decrease the plasma concentrations and therapeutic effects of ribociclib, which is a substrate of the isoenzyme. In healthy study subjects, administration of a single 600 mg dose of ribociclib with multiple 600 mg daily doses of rifampin, a potent CYP450 3A4 inducer, resulted in an 81% and 89% decrease in ribociclib peak plasma concentration (Cmax) and systemic exposure (AUC), respectively, compared to ribociclib administered alone. In addition, administration of efavirenz, a moderate CYP450 3A4 inducer, is predicted to decrease ribociclib Cmax and AUC by 37% and 60%, respectively.
MANAGEMENT: Concomitant use of ribociclib with potent CYP450 3A4 inducers should generally be avoided. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If coadministration is necessary, dosage adjustments as well as clinical and laboratory monitoring should be considered whenever a potent CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for therapeutic failure.
- "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: letrozole / ribociclib
Brand name: Kisqali Femara Co-Pack 200 mg-25 mg Dose, Kisqali Femara Co-Pack 400 mg-25 mg Dose, Kisqali Femara Co-Pack 600 mg-25 mg Dose
Synonyms: n.a.
Generic Name: rifampin
Brand name: Rifadin IV, Rifadin, Rimactane
Synonyms: Rifadin IV (Intravenous), Rifadin IV
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Letrozole and ribociclib-Rifamate
- Letrozole and ribociclib-Rifampin
- Letrozole and ribociclib-Rifampin and Isoniazid
- Letrozole and ribociclib-Rifampin Capsules
- Letrozole and ribociclib-Rifampin Injection
- Letrozole and ribociclib-Rifampin Intravenous
- Rifadin IV Intravenous-Leucovorin
- Rifadin IV Intravenous-Leucovorin Calcium
- Rifadin IV Intravenous-Leucovorin injection
- Rifadin IV Intravenous-Leucovorin Oral, Intravenous, Injection
- Rifadin IV Intravenous-Leucovorin Tablets
- Rifadin IV Intravenous-Leukeran